Микробиом и рак: есть ли связь? Обзор литературы
Аннотация
Микробиом человека находится в тесном взаимодействии с процессами обмена человека и может либо способствовать нашей жизнедеятельности, либо вызвать заболевания, непосредственно изменяя экспрессию генов человека. Проведены многочисленные исследования, направленные на поиск механизмов, с помощью которых микробные сообщества желудочно-кишечного, дыхательного тактов и прочих локусов функционально связаны с процессами метаболизма человека. Сейчас пришло понимание того, что микробиом играет важную и уникальную роль в здоровье и болезни человека. Предпринимаются шаги, направленные на регулирование процессов, происходящих в микробных сообществах. Цели различных исследований в этом направлении многогранны, начиная с регулирования метаболизма человека, иммунной и воспалительной реакций и до предотвращения канцерогенеза, ингибирования прогрессирования рака и повышения эффективности лечения онкологических заболеваний.
Об авторах
Н. С. Багирова
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Министерства здравоохранения РФ.
Россия
Россия
И. H. Петухова
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Министерства здравоохранения РФ.
Россия
Россия
H. В. Дмитриева
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Министерства здравоохранения РФ.
Россия
Россия
З. В. Григорьевская
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Министерства здравоохранения РФ.
Россия
Россия
Список литературы
1. Amy D. Proal, Paul J. Albert, Trevor G. Marshall. Chapter 10, Infection, Autoimmunity, and Vitamin D, in: Infection and autoimmunity, 2015, Second Edition, Edited by Yehuda Shoenfeld Zabludowicz, 163–182. http://dx.doi.org/10.1016/B978‑0‑444‑63269‑2.00007‑6.
2. Курильщиков А. М., Тикунова Н. В., Кабилов М. Р.. Методы и объекты метагеномных исследований. Вестник НГУ, Серия: Биология, клиническая медицина. 2012, Том 12, Выпуск 1, стр. 191–201. http://lib.nsu.ru:8081/xmlui/handle/nsu/5047.
3. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449 (7164):804‑10. doi: 10.1038/nature06244.
4. Methe´ BA, Nelson KE, Pop M, Creasy HH, Giglio MG, Huttenhower C, et al. (248 collaborators: https://www.ncbi.nlm.nih.gov / pubmed / 22699610). Human Microbiome Project Consortium. A framework for human microbiome research. Nature 2012; 486 (7402):215‑21. doi:10.1038/nature11209.
5. Ehrlich SD. MetaHIT: The European Union Project on metagenomics of the human intestinal tract. New York: Springer; 2011, p. 307–16. doi: 10.1007/978‑1‑4419‑7089‑3_15.
6. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, Bourdeau V, Konstorum A, Lallemant B, Zhang R, Mader S, White JH. Large-scale in silico and microarray-based identification of direct 1,25‑dihydroxyvitamin D3 target genes. Mol Endocrinol 2005; 19 (11):2685‑95. doi: 10.1210/me.2005–0106.
7. Шептулина А. Ф., Широкова Е. Н., Ивашкин В. Т. Ядерные рецепторы в регуляции транспорта и метаболизма желчных кислот. Ж. Гепатология (2013), 5:32–45. РЖГГК онлайн – www.gastro-j.ru.
8. X. U. Yongzhong, XIE. Jianping, LI Yao, YUE Jun, CHEV Jianping, CHUNYU Lijuanand WANG Honghai. Using a cDNA microarray to study cellular gene expression altered by Mycobacterium tuberculosis. Chinese Med J 2003; 116 (7): 1070–1073
9. Yenamandra S. P., Klein G., Kashuba E. NUCLEAR RECEPTORS AND THEIR ROLE IN EPSTEIN – BARR VIRUS INDUCED B CELL TRANSFORMATION. Review. Experimental Oncology 2009. 31 (2):67–73.
10. Marshall TG. Vitamin D, discovery outpaces FDA decision making. BioEssays 2008; 30 (2):173–82.
11. Bell NH. Renal and nonrenal 25‑hydroxyvitamin D-1alpha-hydroxylases and their clinical significance. J Bone Miner Res 1998; 13 (3):350‑3. DOI: 10.1359/jbmr.1998.13.3.350.
12. Proal AD, Albert PJ, Marshall TG. Dysregulation of the vitamin D nuclear receptor may contribute to the higher prevalence of some autoimmune diseases in women. Ann NY Acad Sci 2009; 1173:252‑9. doi: 10.1111/j.1749‑6632.2009.04672. x
13. Zhang B., Xie W., Krasowski M. D. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics Pharmacogenomics. 2008. Vol. 11, N 9, 1695–1709. doi: 10.2217/14622416.9.11.1695
14. Jonkera J. W., Liddle C., Downes M. FXR and PXR: Potential therapeutic targets in cholestasis. J. Steroid Biochem. Mol. Biol. 2012. N 130 (0):147–158. doi: 10.1016/j.jsbmb.2011.06.012.
15. Lehmann JM, DD. McKee, MA. Watson, TM. Willson, JT. Moore, and SA. Kliewer. The Human Orphan Nuclear Receptor PXR Is Activated by Compounds That Regulate CYP3A4 Gene Expression and Cause Drug Interactions. J. Clin. Invest. Vol. 102, No. 5, September 1998, 1016–1023. https://doi.org/10.1172/JCI3703.
16. Goran Bertilsson, Jessica Heidrich, Kristian Svensson, Michael Asman, Lena Jendeberg, Mona Sydow-Backman, Rolf Ohlsson, Hans Postlind, Patrik Blomquist, and Anders Berkenstam. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 12208–12213, October 1998. https://doi.org/10.1073/pnas.95.21.12208.
17. Steven A. Kliewer Bryan Goodwin Timothy M. Willson. The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism. Endocrine Reviews, Vol. 23, Issue 5, 1 October 2002, Pages 687–702, https://doi.org/10.1210/er.2001‑0038.
18. Chris S. Smillie, Mark Burnham Smith, Jonathan J Friedman, Otto X. Cordero, Lawrence A David, Eric John Alm. Ecology drives a global network of gene exchange connecting the human microbiome. Nature. 2011 Oct 30; 480 (7376):241‑4. http://doi:10.1038/nature10571.
19. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 2009; 106 (34):14728‑33. doi:10.1073/pnas.0904489106.
20. Brown DG, Rao S, Weir TL, O’Malia J, Bazan M, Brown RJ, Ryan E. P. Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab 2016; Jun 6; 4:11. doi: 10.1186/s40170‑016‑0151‑y.
21. Ginsburg I. Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis 2002; 2:171‑9. doi: 10.1016 / S1473–3099 (02) 00226‑8.
22. Kosuke Mima, Reiko Nishihara, Zhi Rong Qian, Yin Cao, Yasutaka Sukawa, Jonathan A. Nowak, Juhong Yang, Ruoxu Dou, Yohei Masugi, Mingyang Song, Aleksandar D. Kostic, Marios Giannakis, Susan Bullman, Danny A. Milner, Hideo Baba, Edward L. Giovannucci, Levi A. Garraway, Gordon J. Freeman, Glenn Dranoff, Wendy S. Garrett, Curtis Huttenhower, Matthew Meyerson, Jeffrey A. Meyerhardt, Andrew T. Chan, Charles S. Fuchs, MD, and Shuji Ogino. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016 December; 65 (12): 1973–1980. doi:10.1136/gutjnl-2015‑310101.
23. Repass J, Maherali N, Owen K, Biology RPC, Biology RPC. Registered report: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Elife 2016; 5: e10012. doi: 10.7554/eLife.10012.
24. McHardy I. H., Goudarzi M., Tong M., Ruegger P. M., Schwager E., Weger J. R., Graeber T. G., Sonnenburg J. L., Horvath S., Huttenhower C., McGovern D. P. B., Fornace A. J., Borneman J. and Braun J. Integrative analysis of the microbiome and metabolome of the human intestinal mucosal surface reveals exquisite inter-relationships. Microbiome (2013), 1 (17):2‑19. http://www.microbiomejournal.com/content/1/1/17.
25. Changting Meng, Chunmei Bai, Thomas D. Brown, Leroy E. Hood, Qiang Tian. REVIEW. Human Gut Microbiota and Gastrointestinal Cancer. Genomics Proteomics Bioinformatics. 2018 Feb; 16 (1):33–49. doi: 10.1016 /j.gpb.2017.06.002.
26. Jing Wang, Lei Zhao, Han Yan, Juanjuan Che, Li Huihui, Wu Jun, Bing Liu, Bangwei Cao. A metaanalysis and systematic review on the association between human papillomavirus (types 16 and 18) infection and esophageal cancer worldwide. PLoS One 2016; 11 (7): e0159140. https://doi.org/10.1371/journal.pone.0159140.
27. Mohiuddin, Mohammed Khaliq; Chava, Srinivas; Upendrum, Pavani; Latha, Madhavi; Zubeda, Syeda; Kumar, Ajith; Ahuja, Yog Raj; Hasan, Qurratulain; Mohan, Vasavi. Role of human papilloma virus infection and altered methylation of specific genes in esophageal cancer. Asian Pac J Cancer Prev; Vol. 14, Issue 7, 2013, pp. 4187–4193.. doi:10.7314/APJCP.2013.14.7.4187.
28. Ludmir EB, Stephens SJ, Palta M, Willett CG, Czito BG. Human papillomavirus tumor infection in esophageal squamous cell carcinoma. J Gastrointest Oncol. 2015 Jun; 6 (3): 287–295. doi: 10.3978/j.issn.2078‑6891.2015.001.
29. Xu W, Liu Z, Bao Q, Qian Z. Viruses, other pathogenic microorganisms and esophageal cancer. Gastrointest Tumors 2015; 2 (1): 2–13. doi: 10.1159/000380897.
30. Neto AG, Whitaker A, Pei Z. Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma. Semin Oncol 2016; 43:86–96. doi:10.1053/j.seminoncol.2015.09.005.
31. Amir I, Konikoff FM, Oppenheim M, Gophna U, Half EE. Gastric microbiota is altered in oesophagitis and Barrett’s oesophagus and further modified by proton pump inhibitors. Environ Microbiol 2014; 16:2905‑14. doi: 10.1111/1462–2920.12285.
32. Hu Q, Sun TT, Hong J, Fang JY, Xiong H, Meltzer SJ. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a systematic review and meta-analysis. PLoS One 2017; Jan 10, 12 (1): e0169691. doi: 10.1371/journal.pone.0169691.
33. Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Eradication of Helicobacter pylori and gastric cancer: a systematic review and meta-analysis of cohort studies. J Natl Cancer Inst. 2016 Jul 14; 108 (9). pii: djw132. doi: 10.1093/jnci/djw132.
34. De Witte C, Schulz C, Smet A, Malfertheiner P, Haesebrouck F. Other Helicobacters and gastric microbiota. Helicobacter. 2016 Sep; 21 Suppl 1:62‑8. doi:10.1111/hel.12343.
35. Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, Karaoz U, Contreras M, Blaser MJ, Brodie EL, Dominguez-Bello MG. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME J. 2011 Apr; 5 (4):574‑9. doi: 10.1038/ismej.2010.149. Epub 2010Oct7.
36. Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F, Guillermo Perez-Perez, Martin J. Blaser, and David A. Relman. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A. 2006 Jan 17; 103 (3):732‑7. Epub 2006 Jan 4. doi: 10.1073pnas.0506655103.
37. Iizasa H, Ishihara S, Richardo T, Kanehiro Y, Yoshiyama H. Dysbiotic infection in the stomach. World J Gastroenterol. Oct 28, 2015; 21 (40): 11450–11457. doi: 10.3748/wjg.v21.i40.11450.
38. Aviles-Jimenez F, Vazquez-Jimenez F, Medrano-Guzman R, Mantilla A, Torres J. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci Rep. 2014 Feb 26; 4:4202. doi: 10.1038/srep04202.
39. Dias-Jacome E, Libanio D, Borges-Canha M, Galaghar A, Pimentel-Nunes P. Gastric microbiota and carcinogenesis: the role of non-Helicobacter pylori bacteria – a systematic review. Rev Esp Enferm Dig. 2016 Sep; 108 (9):530–40. doi: 10.17235/reed.2016.4261/2016.
40. Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol. 2011 Jan; 11 (1):9–20. doi: 10.1038/nri2891. Epub 2010 Dec 10.
41. Tomasello G, Tralongo P, Damiani P, Sinagra E, Di Trapani B, Zeenny MN, Hussein IH, Jurjus A, Leone A. Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes. World J Gastroenterol. 2014 Dec 28; 20 (48):18121‑30. doi: 10.3748/wjg.v20.i48.18121.
42. Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, Cosnes J, Seksik P, Langella P, Skurnik D, Richard ML, Beaugerie L. Fungal microbiota dysbiosis in IBD. Gut. 2017 Jun; 66 (6): 1039–1048. doi: 10.1136/gutjnl-2015‑310746.
43. Prindiville TP, Sheikh RA, Cohen SH, Tang YJ, Cantrell MC, Silva J. Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease. Emerg Infect Dis 2000; 6 (2):171‑4. doi: 10.3201/eid0602.000210.
44. Basset C, Holton J, Bazeos A, Vaira D, Bloom S. Are Helicobacter species and enterotoxigenic Bacteroides fragilis involved in inflammatory bowel disease? Dig Dis Sci 2004; 49:1425‑32. doi.org/10.1023/B:DDAS.0000042241.13489.88.
45. Ou B, Zhao J, Guan S, Lu A. Survival of colorectal cancer in patients with or without inflammatory bowel disease: a metaanalysis. Dig Dis Sci. 2016 Mar; 61 (3):881‑9. doi: 10.1007/s10620‑015‑3940‑1. Epub 2015 Oct 30.
46. Wu S, Powell J, Mathioudakis N, Kane S, Fernandez E, Sears CL. Bacteroides fragilis enterotoxin induces intestinal epithelial cell secretion of interleukin-8 through mitogen-activated protein kinases and a tyrosine kinase-regulated nuclear factor-kappaB pathway. Infect Immun 2004; 72 (10):5832‑9. doi: 10.1128/IAI.72.10.5832‑5839.2004.
47. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, Sears CL. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009; 15 (9):1016‑22. doi: 10.1038/nm.2015.Epub2009Aug 23.
48. Coleman OI, Nunes T. Role of the microbiota in colorectal cancer: updates on microbial associations and therapeutic implications. Biores Open Access 2016;5 (1): 279‑88. doi: 10.1089/biores.2016.0028
49. Gagnie`re J, Raisch J, Veziant J, Barnich N, Bonnet R, Buc E, Bringer MA, Pezet D, Bonnet M.. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 2016; 22 (2):501‑18. doi: 10.3748/wjg.v22.i2.501.
50. Shen XJ, Rawls JF, Randall T, Burcal L, Mpande CN, Jenkins N, Jovov B, Abdo Z, Sandler RS, Keku TO. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes 2010; 1 (3):138‑47. doi: 10.4161/gmic.1.3.12360. Epub 2010 May 13.
51. Wang C, Li J. Pathogenic microorganisms and pancreatic cancer. Gastrointest Tumors 2015; 2 (1):41‑7. doi: 10.1159 / 000380896.
52. Michaud DS, Izard J. Microbiota, oral microbiome, and pancreatic cancer. Cancer J 2014; 20 (3):203‑6. DOI: 10.1097/PPO.0000000000000046.
53. Zambirinis CP, Pushalkar S, Saxena D, Miller G. Pancreatic cancer, inflammation, and microbiome. Cancer J 2014; 20:195–202.
54. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9 (11):798–809. doi: 10.1038/nrc2734.
55. Warzecha Z, Dembinґ ski A, Ceranowicz P, Dembinґ ski M, Sendur R, Pawlik WW, Konturek SJ. Deleterious effect of Helicobacter pylori infection on the course of acute pancreatitis in rats. Pancreatology 2002; 2 (4):386‑95. DOI: 10.1159/000065086.
56. Niemann T, Larsen S, Mouritsen EA, Thorsgaard N. Helicobacter pylori infection in patients with chronic pancreatitis and duodenal ulcer. Scand J Gastroenterol 1997; 32 (12):1201‑3.
57. Manes G, Dominguez-Mun oz JE, Hackelsberger A, Leodolter A, RoЁ ssner A, Malfertheiner P. Prevalence of Helicobacter pylori infection and gastric mucosal abnormalities in chronic pancreatitis. Am J Gastroenterol 1998; 93 (7):1097‑100. DOI: 10.1111/j.1572‑0241.1998.336_b.x.
58. Kountouras J, Zavos C, Chatzopoulos D. A concept on the role of Helicobacter pylori infection in autoimmune pancreatitis. J Cell Mol Med 2005; 9 (1):196‑207.
59. Wormann SM, Diakopoulos KN, Lesina M, Algul H. The immune network in pancreatic cancer development and progression. Oncogene. 2014 Jun 5; 33 (23):2956‑67. doi: 10.1038/onc.2013.257. Epub 2013 Jul 15.
60. Carvalho BM, Saad MJ. Influence of gut microbiota on subclinical inflammation and insulin resistance. Hindawi Publishing Corporation Mediators of Inflammation, 2013, Volume 2013, Article ID 986734, 13 pages. http://dx.doi.org/10.1155/2013/986734.
61. Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, Izzo F, La Vecchia C, Boffetta P, Montella M. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer 2013; 108 (1):222‑8. doi: 10.1038/bjc.2012.492. Epub 2012 Nov 20.
62. Borena W, Strohmaier S, Lukanova A, Bjшrge T, Lindkvist B, Hallmans G, Edlinger M, Stocks T, Nagel G, Manjer J, Engeland A, Selmer R, Haggstrom C, Tretli S, Concin H, Jonsson H, Stattin P, Ulmer H. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer 2012; 131 (1):193‑200. doi: 10.1002/ijc.26338. Epub 2011 Sep 8.
63. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Honda K, Ishikawa Y, Hara E, Ohtani N. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499 (7456):97–101. doi: 10.1038/nature12347. Epub 2013 Jun 26.
64. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140 (2):197‑208. doi: 10.1016/j.cell.2009.12.052.
65. Ohtani N. Microbiome and cancer. Semin Immunopathol. 2015 Jan; 37 (1):65–72. doi: 10.1007/s00281‑014‑0457‑1. Epub 2014 Nov 18.
66. Chng KR, Chan SH, Ng AH, Li C, Jusakul A, Bertrand D, Andreas Wilm, Su Pin Choo, Damien Meng Yew Tan, Kiat Hon Lim, Roy Soetinko, Choon Kiat Ong, Dan G. Duda, Simona Dimah Irinel Popescu, Chaisiri Wongkham, Zhu Feng, Khay Guan Yeoh, Bin Tean Teh, Puangrat Yongvanit, Sopit Wongkham, Vajaraphongsa Bhudhisawasdi, Narong Khuntikeo, Patrick Tan, Chawalit Pairojkul, Joanne Ngeow, and Niranjan Nagarajan. Tissue microbiome profiling identifies an enrichment of specific enteric bacteria in Opisthorchis viverrini associated cholangiocarcinoma. EBioMedicine 2016; 8:195–202. doi: 10.1016/j.ebiom.2016.04.034.
67. Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet. 2014 Aug 23; 384 (9944):691–702. doi: 10.1016/S0140–6736(14)61136‑3.
68. Dickson RP, Erb-Downward JR, Huffnagle GB. The role of the bacterial microbiome in lung disease. Expert Rev Respir Med. 2013; 7 (3): 245–257. doi: 10.1586/ers.13.24.
69. Bingula R., Filaire M., Radosevic-Robin N., Bey M., Berthon J.‑Y., Bernalier-Donadille A, Vasson M.‑P., Filaire E. Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer. Review Article. Journal of Oncology, Vol. 2017, Article ID 5035371, 15 p., https://doi.org/10.1155/2017/5035371.
70. Markus Hilty, Conor Burke, Helder Pedro, Paul Cardenas, Andy Bush, Cara Bossley, Jane Davies, Aaron Ervine, Len Poulter, Lior Pachter, Miriam F. Moffatt, William O. C. Cookson. Disordered microbial communities in asthmatic airways, PLoS ONE, vol. 5, no. 1, Article ID e8578, 2010. https://doi.org/10.1371/journal.pone.0008578.
71. Wang H, Liu JS, Peng SH, Deng XY, Zhu DM, Javidiparsijani S, Wang GR, Li DQ, Li LX, Wang YC, Luo JM. World J Gastroenterol. 2013 Oct; 19 (40):6794‑804. doi:10.3748/wjg.v19.i40.6794.
72. Jess T., Horvґath-Puhґo E., Fallingborg J., Rasmussen H. H., Jacobsen B. A., Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study, Am J Gastroenterol. 2013 Dec; 108 (12):1869‑76. doi: 10.1038/ajg.2013.249. Epub 2013 Aug 27.
73. Keely S., Talley N. J., Hansbro P. M., Pulmonary-intestinal cross-talk inmucosal inflammatory disease, Mucosal Immunology, 2012, 5 (1): 7–18. doi: 10.1038/mi.2011.55.
74. Goddard F., Staudinger B. J., Dowd S. E., Amruta J.‑D., Wolcott R. D., Aitken M. L., Flignerf C. L., Pradeep K. S. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Natl Acad Sci U S A. 2012 Aug 21; 109 (34): 13769–13774. doi: 10.1073/pnas.1107435109.
75. Sze M. A., Dimitriu P. A., Hayashi S., Elliott W. M., McDonough J. E., Gosselink J. V., Cooper J., Sin D. D., W. M. William, Hogg J. C. The lung tissue microbiome in chronic obstructive pulmonary disease, Am J Respir Crit Care Med. 2012 May 15; 185 (10): 1073–1080. doi: 10.1164/rccm.201111-2075OC.
76. S. Raviv, K. A. Hawkins, M. M. DeCamp Jr., Kalhan R., Lung cancer in chronic obstructive pulmonary disease: Enhancing surgical options and outcomes, Am J Respir Crit Care Med. 2011, 183 (9): 1138‑1146, 2011. doi: 10.1164/rccm.201008-1274CI.
77. El-Telbany A., Ma P. C., Cancer genes in lung cancer: racial disparities: are there any? Genes and Cancer, Vol. 3, Issue 7‑8, 2012, Pages 467–480. doi: 10.1177/1947601912465177.
78. Chen D. S., Mellman I., Oncology meets immunology: the cancer-immunity cycle, Immunity, 2013 Jul 25; 39 (1):1–10, doi: 10.1016/j.immuni.2013.07.012.
79. Wendy R. Brewster, Emily Meichun Ko, Temitope O Keku. An evaluation of the microbiota of the upper genital tract of women with benign changes and epithelial ovarian cancer. J Clin Oncol 34 (15), 2016 (suppl; abstr 5568. 2016 ASCO Annual Meeting). doi: 10.1200/JCO.2016.34.15_suppl.5568.
80. Camilla Urbaniak, Gregory B. Gloor, Muriel Brackstone, Leslie Scott, Mark Tangney, Gregor Reid. The Microbiota of Breast Tissue and Its Association with Breast Cancer. Applied and Environmental Microbiology. 2016, 82 (16): 5039–5048. doi: 10.1128/AEM.01235‑16.
81. Pandey KR., Naik SR., Vakil BV. Probiotics, prebiotics and synbiotics – a review. J. Food Sci. Technol. 2015. Dec.; 52 (12): 7577‑87. doi: 10.1007/s13197‑015‑1921‑1. Epub 2015 Jul 22.
82. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997; 111 (3):623‑31. doi: https://doi.org/10.1378/chest.111.3.623.
83. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA. 2013 Feb 26; 110 (9):3507‑12. doi: 10.1073/pnas.1222878110. Epub 2013 Feb 11.
84. Leslie M. Microbiome. Microbes aid cancer drugs. Science. 2015 Nov 6; 350 (6261):614‑5. doi: 10.1126/science.350.6261.614.
85. Veґtizou M, Pitt JM, Daille`re R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Berard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoul D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015 Nov 27; 350 (6264):1079‑84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.
86. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Franco W. Benyamin, Yuk Man Lei, Bana Jabri, Maria-Luisa Alegre, Eugene B. Chang, Thomas F. Gajewski. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD‑L1 efficacy. Science. 2015 Nov 27; 350 (6264): 1084‑1089. doi: 10.1126/science.aac4255.
87. Zhu Y, Michelle Luo T, Jobin C, Young HA. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett. 2011 October 28; 309 (2): 119‑27. doi:10.1016/j.canlet.2011.06.004
88. Tojo R, Suaґ rez A, Clemente MG, de los Reyes-Gavilaґn CG, Margolles A, Gueimonde M, Ruas-Madiedo P. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol. 2014, Nov 7; 20 (41):15163‑76. doi: 10.3748/wjg.v20.i41.15163.
89. Ambalam P, Raman M, Purama RK, Doble M. Probiotics, prebiotics and colorectal cancer prevention. Best Pract Res Clin Gastroenterol 2016; 30 (1):119‑31. doi: 10.1016/j.bpg.2016.02.009. Epub 2016 Feb 19.
90. Gianotti L, Morelli L, Galbiati F, Rocchetti S, Coppola S, Beneduce A, Gilardini C, Zonenschain D, Nespoli A, Braga M. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol. 2010 Jan 14; 16 (2):167‑75. doi: 10.3748/wjg.v16.i2.167.
91. Zhang M, Fan X, Fang B, Zhu C, Zhu J, Ren F. Effects of Lactobacillus salivarius Ren on cancer prevention and intestinal microbiota in 1,2‑dimethylhydrazine-induced rat model. J Microbiol. 2015 Jun; 53 (6):398–405. doi: 10.1007/s12275‑015‑5046‑z. Epub 2015 May 30.
92. Kuugbee ED, Shang X, Gamallat Y, Bamba D, Awadasseid A, Suliman MA, Zang S, Ma Y, Chiwala G, Xin Y, Shang D. Structural change in microbiota by a probiotic cocktail enhances the gut barrier and reduces cancer via TLR2 signaling in a rat model of colon cancer. Dig Dis Sci. 2016 Oct; 61 (10):2908–2920. doi: 10.1007/s10620‑016‑4238‑7. Epub 2016 Jul 6.
93. Li J, Sung CY, Lee N, Ni Y, Pihlajamaki J, Panagiotou G, El-Nezami H. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A. 2016 Mar 1; 113 (9):E1306–15. doi: 10.1073/pnas.1518189113. Epub 2016 Feb 16.
94. Jakobsson HE, Jernberg C, Andersson AF, SjoЁ lund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010 Mar 24; 5 (3):e9836. doi: 10.1371/journal.pone.0009836.
95. Oh B, Kim BS, Kim JW, Kim JS, Koh SJ, Kim BG, Lee KL, Chun J. The effect of probiotics on gut microbiota during the Helicobacter pylori radication: randomized controlled trial. Helicobacter 2016; 21 (3):165‑74. doi: 10.1111/hel.12270. Epub 2015 Sep 23.
96. Motoori M, Yano M, Miyata H, Sugimura K, Saito T, Omori T, Fujiwara Y, Miyoshi N, Akita H, Gotoh K, Takahashi H, Kobayashi S, Noura S, Ohue M, Asahara T, Nomoto K, Ishikawa O, Sakon M. Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. Clin Nutr 2017; 36 (1):93‑9. doi: 10.1016/j.clnu.2015.11.008. Epub 2015 Nov 25.
97. Abreu MT, Peek RM. Gastrointestinal malignancy and the microbiome. Gastroenterology. 2014 May; 146 (6): 1534–1546.e3. doi: 10.1053/j.gastro.2014.01.001.
98. Panos Lehouritis, Joanne Cummins, Michael Stanton, Carola T. Murphy, Florence O. McCarthy, Gregor Reid, Camilla Urbaniak, William L. Byrne & Mark Tangney. Local bacteria affect the efficacy of chemotherapeutic drugs. 2015. Scientific Reports 5:14554. doi: 10.1038/srep14554.
99. Fukata M, Abreu MT. Microflora in colorectal cancer: a friend to fear. Nat Med 2010; 16:639‑41. doi: 10.1038/nm0610–639.
100. Wallace B. D., Venkatesh M., Jobin C., Li-An Yeh., Mani S., Redinbo M. R. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010; 330:831‑5. doi: 10.1126/science.1191175.
101. Lin XB, Dieleman LA, Ketabi A, Bibova I, Sawyer MB, Xue H, Field C. J., Baracos V. E., Ganzle M. G. Irinotecan (CPT- 1) chemotherapy alters intestinal microbiota in umour bearing rats. PLoS ONE 7(7): e39764. doi: 10.1371/journal.pone.0039764.
Рецензия
Для цитирования:
Багирова Н.С., Петухова И.H., Дмитриева H.В., Григорьевская З.В. Микробиом и рак: есть ли связь? Обзор литературы. Злокачественные опухоли. 2018;8(3s1):56-69.
Просмотров: 745
Послать статью по эл. почте 